HC Wainwright initiated coverage on shares of Geron (NASDAQ:GERN – Free Report) in a research report report published on Tuesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $8.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Geron’s Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings […]

Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its price target boosted by B. Riley from $194.00 to $236.00 in a research note released on Tuesday,Benzinga reports. B. Riley currently has a neutral rating on the biopharmaceutical company’s stock. B. Riley also issued estimates for Madrigal Pharmaceuticals’ Q4 2024 earnings at ($3.86) EPS, FY2024 earnings at […]

Flushing Financial Co. (NASDAQ:FFIC – Free Report) – Research analysts at DA Davidson raised their FY2024 earnings per share estimates for Flushing Financial in a report released on Thursday, November 7th. DA Davidson analyst M. Navas now anticipates that the bank will post earnings of $0.78 per share for the year, up from their prior […]

Wedbush restated their outperform rating on shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) in a research note issued to investors on Tuesday morning,RTT News reports. The brokerage currently has a $57.00 target price on the stock. Wedbush also issued estimates for Beam Therapeutics’ Q4 2024 earnings at ($1.21) EPS, FY2024 earnings at ($4.69) EPS, […]

Revolution Medicines (NASDAQ:RVMD – Get Free Report) had its price target lifted by equities research analysts at HC Wainwright from $62.00 to $64.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 7.26% from the company’s […]

TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) – Equities researchers at B. Riley reduced their FY2027 EPS estimates for shares of TG Therapeutics in a research report issued on Monday, November 4th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will earn $2.46 per share for the year, down from their prior […]

Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) – Equities research analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Krystal Biotech in a research note issued to investors on Monday, November 4th. HC Wainwright analyst J. Pantginis now anticipates that the company will earn $3.64 per share for the year, down […]

Boise Cascade (NYSE:BCC – Free Report) – DA Davidson cut their FY2024 earnings per share (EPS) estimates for Boise Cascade in a research note issued to investors on Wednesday, November 6th. DA Davidson analyst K. Yinger now expects that the construction company will earn $9.62 per share for the year, down from their prior estimate […]

5N Plus Inc. (TSE:VNP – Free Report) – Stock analysts at Raymond James boosted their FY2024 earnings per share (EPS) estimates for shares of 5N Plus in a research report issued on Tuesday, November 5th. Raymond James analyst M. Glen now forecasts that the company will post earnings of $0.29 per share for the year, […]